Drug Clinical Trials List

Display 321 - 330 from 730

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	AstraZeneca	Completed	AZD9291	3	D5160C00007	KFSH&RC-R
A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	Astrazeneca	Ongoing	Trastuzumab-deruxtecan (Enhertu)	3	D967UC00001	King Fahad Specialist Hospital (Dammam)
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)	AstraZeneca	Completed	MEDI4736+Tremelimumab	3	D419AC00003	KKUH
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation	Novartis	Completed	Ruxolitinib (INC424) (Jakavi)	3	CINC424C2301	KFSH&RC-R
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation	Novartis	Ongoing	Ruxolitinib (INC424) (Jakavi)	3	CINC424D2301	KFSH & RC-R
A Phase III Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy	MSD	Completed	SITAGLIPTIN/ METFORMIN XR	3	MK0431A XR-289	KKUH
"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"	AstraZeneca	Ongoing	Capivasertib	3	D3614C00001	KFSH-D
A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study)	KAIMRC	Ongoing	DOXORUBICIN HYDROCHLORIDE	2	RC16/150	NGHA-R
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease.	Modus Therapeutics AB	Ongoing	Sevuparin	3	TVOC01	KKUH
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study.	Novartis	Terminated	ribociclib	2	CLEE011A3201C	King Faisal Specialist Hospital and Research Center (Riyadh)